The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy: Analysis of the surveillance, epidemiology, and end results database

Cancer

Volumn 110, Issue 4, 2007, Pages 911-917

  Lally, Brian E ^a   Detterbeck, Frank C ^b   Geiger, Ann M ^a   Thomas Jr , Charles R ^c   Machtay, Mitchell ^d   Miller, Antonius A ^a   Wilson, Lynn D ^b   Oaks, Timothy E ^a   Petty, W Jeffrey ^a   Robbins, Mike E ^a   Blackstock, A William ^a  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Adjuvant therapy; And End Results; Cardiac mortality; Epidemiology; Intercurrent death; Nonsmall cell lung cancer; Radiation therapy; Surgery; Surveillance

Indexed keywords

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEALTH PROGRAM; HEART DISEASE; HISTOPATHOLOGY; HUMAN; LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; POSTOPERATIVE CANCER RADIOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; TREATMENT PLANNING;

AFRICAN AMERICANS; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEART DISEASES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREVALENCE; REGISTRIES; RISK FACTORS; SURVIVAL RATE; UNITED STATES;

EID: 34547889093     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22845     Document Type: Article

References (36)

1. Van Houtte P, Rocmans P, Smets P, et al. Postoperative radiation therapy in lung caner: a controlled trial after resection of curative design. Int J Radiat Oncol Biol Phys. 1980;6:983-986.
2. Trodella L, Granone P, Valente S, et al. Adjuvant radiotherapy in non-small cell lung cancer with pathological stage I: definitive results of a phase III randomized trial. Radiother Oncol. 2002;62:11-19.
3. Stephens RJ, Girling DJ, Bleehen NM, Moghissi K, Yosef HM, Machin D. The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Medical Research Council Lung Cancer Working Party. Br J Cancer. 1996;74:632-639.
4. Mayer R, Smolle-Juettner FM, Szolar D, et al. Postoperative radiotherapy in radically resected non-small cell lung cancer. Chest. 1997;112:954-959.
5. Keller SM, Adak S, Wagner H, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med. 2000;343:1217-1222.
6. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. The Lung Cancer Study Group. N Engl J Med. 1986;315:1377-1381.
7. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet. 1998;352:257-263.
8. Dautzenberg B, Arriagada R, Chammard AB, et al. A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. Groupe d'Etude et de Traitement des Cancers Bronchiques. Cancer. 1999;86:265-273.
9. Wakelee HA, Stephenson P, Keller SM, et al. Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590. Lung Cancer. 2005;48:389-397.
10. Bonner JA. The role of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma: seeking to optimize local control and survival while minimizing toxicity. Cancer. 1999;86:195-196.
11. Machtay M, Kaiser LR, Glatstein E. Reality and meta-analyses. Chest. 2000;118:835-836.
12. Marks LB, Prosnitz LR. Postoperative radiotherapy for lung cancer: the breast cancer story all over again? Int J Radiat Oncol Biol Phys. 2000;48:625-627.
13. Munro AJ. What now for postoperative radiotherapy for lung cancer? Lancet. 1998;352:250-251.
14. Bogart JA, Aronowitz JN. Localized non-small cell lung cancer: adjuvant radiotherapy in the era of effective systemic therapy. Clin Cancer Res. 2005;11(13 pt 2):5004s-5010s.
15. Phlips P, Rocmans P, Vanderhoeft P, Van HP. Postoperative radiotherapy after pneumonectomy: impact of modern treatment facilities. Int J Radiat Oncol Biol Phys. 1993;27:525-529.
16. Roach M III, Gandara DR, Yuo HS, et al. Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol. 1995;13:2606-2612.
17. Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the Surveillance, Epidemiology, and End Results database. J Clin Oncol. 2006;24:2998-3006.
18. Ergin A, Muntner P, Sherwin R, He J. Secular trends in cardiovascular disease mortality, incidence, and case fatality rates in adults in the United States. Am J Med. 2004;117:219-227.
19. Arciero TJ, Jacobsen SJ, Reeder GS, et al. Temporal trends in the incidence of coronary disease. Am J Med. 2004;117:228-233.
20. McCullough EC, Baker HL Jr, Houser OW, Reese DF. An evaluation of the quantitative and radiation features of a scanning x-ray transverse axial tomograph: the EMI scanner. Radiology. 1974;111:709-715.
21. McCullough EC. Potentials of computed tomography in radiation therapy treatment planning. Radiology. 1978;129:765-768.
22. Geise RA, McCullough EC. The use of CT scanners in megavoltage photon-beam therapy planning. Radiology. 1977;124:133-141.
23. Chen GT, Pelizzari CA, Spelbring DR, Awan A. Evaluation of treatment plans using dose volume histograms. Front Radiat Ther Oncol. 1987;21:44-55.
24. Armstrong JG, Burman C, Leibel S, et al. Three-dimensional conformal radiation therapy may improve the therapeutic ratio of high dose radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys. 1993;26:685-689.
25. Bogardus C Jr. The correct usage of the new radiation oncology codes. 77395 - 3-dimensional simulation; 77419 - conformal weekly radiation therapy treatment management; 77432 - stereotactic treatment management. Adm Radiol. 1994;13:53-56.
26. Stewart JR, Fajardo LF, Gillette SM, Constine LS. Radiation injury to the heart. Int J Radiat Oncol Biol Phys. 1995;31:1205-1211.
27. Paszat LF, Mackillop WJ, Groome PA, Boyd C, Schulze K, Holowaty E. Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the Surveillance, Epidemiology, and End-Results cancer registries. J Clin Oncol. 1998;16:2625-2631.
28. Gagliardi G, Lax I, Ottolenghi A, Rutqvist LE. Long-term cardiac mortality after radiotherapy of breast cancer - application of the relative seriality model. Br J Radiol. 1996;69:839-846.
29. Giordano SH, Kuo YF, Freeman JL, Buchholz TA, Hortobagyi GN, Goodwin JS. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst. 2005;97:419-424.
30. Douillard JY, Rosell R, De LM, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7:719-727.
31. Arriagada R, Bergman B, Dunant A, Le CT, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351-360.
32. Sedrakyan A, Van Der MJ, O'Byrne K, Prendiville J, Hill J, Treasure T. Postoperative chemotherapy for non-small cell lung cancer: a systematic review and meta-analysis. J Thorac Cardiovasc Surg. 2004;128:414-419.
33. Strauss GM, Herndon J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 2004;22. Abstract 7019.
34. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589-2597.
35. Turrisi A, Keller S. Since chemotherapy is now the standard in node-positive lung cancer, what is the role of postoperative radiotherapy? J Clin Oncol. 2007;25:459-460.
36. Hanna NH, Einhorn LH. Postoperative chemotherapy for N2 non-small-cell lung cancer: conclusions are not black and white, but gray. J Clin Oncol. 2006;24:5611-5612.